Exhibit 99.1

  MediCor Ltd. Reports Third Quarter Results and Year-to-Date Sales
                             Growth of 20%

    LAS VEGAS--(BUSINESS WIRE)--May 16, 2005--MediCor Ltd.
(OTCBB:MDCR) announced today its financial results for the quarter
ending March 31, 2005.
    Sales for the third quarter of fiscal year 2005 were $7.1 million,
an increase of $6.6 million over the prior year quarter. On a pro
forma basis, sales for the quarter ending March 31, 2005, increased
about $0.6 million or approximately 8% over the comparable prior year
quarter. Pro forma results are shown because MediCor's results include
the substantial benefit from the acquisition of Eurosilicone S.A.S. on
July 5, 2004, which was not part of MediCor's results in the prior
year quarter. Additionally, sales for the latest three quarters
equaled $19.4 million, an increase of $3.2 million or approximately
20%, as compared to the prior year, pro forma period.
    Additionally, the company recently filed a current report on Form
8-K announcing that its wholly owned subsidiary, MediCor Aesthetics,
will be the exclusive distributor in the United States for Biosil
inflatable saline breast implants. Simultaneously, the company
acquired the assets of Hutchison International Inc., the former Biosil
distributor in the United States. The asset purchase was effected
primarily to facilitate the transition from Hutchison to MediCor as
the new U.S. distributor.
    MediCor Ltd. Chief Operating Officer, Jim J. McGhan, commented,
"The transaction represents another key component of MediCor's
strategy to enter the United States' breast implant market." He added,
"By entering into the long-term agreement with Biosil, MediCor is able
to work cooperatively toward the completion of the premarket approval
application, while developing the working relationships essential for
the successful commercialization of the product. While
commercialization of the Biosil breast implant remains dependent upon
United States Food and Drug Administration approval of the premarket
approval application, and there can be no assurance such approval will
be forthcoming, we now have the opportunity to draw upon highly
skilled and experienced professionals from both companies to achieve
the objective."

    About MediCor

    MediCor Ltd. is a global health care company that acquires,
develops, manufactures and markets products primarily for the
aesthetic, plastic surgery and dermatology markets. Current products
include breast and other implants and scar management products. Its
Eurosilicone subsidiary's breast implant products are sold in
approximately 85 countries, but are not currently sold in the United
States or Canada. Eurosilicone develops, manufactures and markets a
full range of breast implants for the aesthetic, plastic and
reconstructive surgery markets, including both silicone gel and
inflatable saline-filled breast implants. Eurosilicone also markets a
line of external breast prostheses under the Maxima brand, as well as
a wide range of other silicone implants, including tissue expanders,
testicular, gluteal and calf implants, and a full line of facial
implants. The company's products are sold worldwide to hospitals,
surgery centers and physicians through a combination of independent
distributors and direct sales personnel.
    MediCor's objective is to be a leading supplier of selected
international medical devices and technologies. To achieve this
objective, MediCor intends to build upon and expand its business
lines, primarily in the aesthetic, plastic and reconstructive surgery
and dermatology markets. MediCor intends to accomplish this growth
through the expansion of existing product lines and offerings, and
through the acquisition of companies and other assets, including
intellectual property rights and distribution rights.

    Forward-Looking Statements

    Statements in this press release may involve forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995, including forward-looking statements regarding
MediCor's future strategies and growth plans and about market growth.
Such statements are based upon the current beliefs and expectations of
MediCor's management and are subject to significant risks and
uncertainties, including but not limited to external factors such as:
clinical trials, government regulation, agreements with third-party
manufacturers, product liability or other legal factors, capital
markets and the ability to obtain additional financing, economic
factors and changes in customer spending, and other factors over many
of which management has no control. These forward-looking statements
should be evaluated together with additional information about
MediCor's business, markets, conditions and other risks and
uncertainties, which could affect MediCor's future performance, which
are contained in MediCor's Annual Report on Form 10-KSB for the year
ended June 30, 2004, and its quarterly report on Form 10-QSB for the
quarter ended March 31, 2005, and its other filings with the
Securities and Exchange Commission available at the Securities and
Exchange Commission's Internet site (http://www.sec.gov), which are
incorporated into this press release by reference. Actual results may
vary materially because of risks and uncertainties. This press release
speaks only as of its date, and MediCor disclaims any duty to update
the information herein.

    CONTACT: MediCor Ltd., Las Vegas
             Marc S. Sperberg, 702-932-4560, ext. 308